Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
Newcorn
Jeffrey H
JH
Mount Sinai School of Medicine, New York, NY, USA. jeffrey.newcorn@exchange.mssm.edu
Donnelly
Craig
C
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology; D002170:Canada; D002319:Cardiovascular System / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D004562:Electrocardiography; D006801:Humans; D008403:Mass Screening; D017410:Practice Guidelines as Topic; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000697:Central Nervous System Stimulants